Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer's Disease Neuroimaging Initiative).
BACKGROUND
The purpose of this study was to investigate the relationship between cognitive reserve and concentration of Aβ1-42 in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment, those with Alzheimer's disease, and in control subjects.


METHODS
Thirty-three participants from the Argentina-Alzheimer's Disease Neuroimaging Initiative database completed a cognitive battery, the Cognitive Reserve Questionnaire (CRQ), and an Argentinian accentuation reading test (TAP-BA) as a measure of premorbid intelligence, and underwent lumbar puncture for CSF biomarker quantification.


RESULTS
The CRQ significantly correlated with TAP-BA, education, and Aβ1-42. When considering Aβ1-42 levels, significant differences were found in CRQ scores; higher levels of CSF Aβ1-42 were associated with higher CRQ scores.


CONCLUSIONS
Reduced Aβ1-42 in CSF is considered as evidence of amyloid deposition in the brain. Previous results suggest that individuals with higher education, higher occupational attainment, and participation in leisure activities (cognitive reserve) have a reduced risk of developing Alzheimer's disease. Our results support the notion that enhanced neural activity has a protective role in mild cognitive impairment, as evidenced by higher CSF Aβ1-42 levels in individuals with more cognitive reserve.
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
Paula
P
Harris
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
Marcos
M
Fernandez Suarez
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
Ezequiel I
EI
Surace
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
Patricio
P
Chrem Méndez
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
María Eugenia
ME
Martín
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
María Florencia
MF
Clarens
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
Fernanda
F
Tapajóz
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
Maria Julieta
MJ
Russo
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
Jorge
J
Campos
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
Salvador M
SM
Guinjoan
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina.
Gustavo
G
Sevlever
Instituto de Investigaciones Neurológicas, Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
Ricardo F
RF
Allegri
Alzheimer’s disease; amyloid; biomarkers; cerebrospinal fluid